drug
Rybelsus
Marketedupdated 3mo agoby Novo Nordisk Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOzempic121 co-mentions · 73 sources
- drugWegovy121 co-mentions · 73 sources
- drugWegovy Pill94 co-mentions · 72 sources
- tagApproval88 co-mentions · 44 sources
- drugsemaglutide72 co-mentions · 72 sources
- tagRecall29 co-mentions · 27 sources
- tagSmall Molecule17 co-mentions · 17 sources
- companyNovo Nordisk Inc11 co-mentions · 4 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Rybelsus
- phase3A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- phase3A Study of BGM0504 in Early T2DM With Obesity
- phase2Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase4Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
- phase1Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
News(10)
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 6d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 6d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 6d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 7d ago
- FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s dataReplimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.biopharma_dive · 13d ago
- Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtShareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artific…biospace · 13d ago
- Novo Nordisk fails to dismiss lawsuit over CagriSema readoutNovo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.fiercebiotech · 13d ago
- Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winAn experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectively harnessed again…fiercebiotech · 14d ago
- Chutes & Ladders—Biogen R&D vet gets in FormationAI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers, M.D., Ph.D., is joining the 2025 Fierce 15 honoree as chief s…fiercebiotech · 19d ago
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.biospace · 21d ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that